Now difficult to put price on Anab. Till now All (important) trials failed. Also not sure about their cash because the $250 million is booked as "liabilities". In simple english its a kind of a loan....that they do not need to pay back if they met some milestones. So the real cash is around $300m Thats $12/share. If the salesfigures of Jemperli are bad..... If they are better then expected.... So its a kind of guessing now. 1 thing for sure, they did not find a buyer. Means...nobody saw real value in Anab.
And even they would have success with phase 3 trial. Thats not big money...and will cost $50 tp $ 100 million to start selling it...etc If XBI will trend up, Anab will go higher from here. But $37 was good money. Thats why Hamza sold a lot.
280,000 shares acquired by Suria Hamza (President, CEO), form 4 filed with the SEC
280,000 shares acquired by Suria Hamza (President, CEO), form 4 filed with the SEC
newsfilter.io
Y
I feel like ANAB was oversold today, it could be a good entry point with some obvious risk tied in. If ANAB is able to deliver well on what it has in its pipeline things could be looking on the upside. I still feel like it will have a rebound in the short-term but long-term is more risky but more risk means higher return we will just have to hope that the company is able to deliver and we could see some nice gains and revenues are up $4.8 Million up about 55% year over year so thats also a positive maybe the company will be able to make profits soon if all goes well. But I'll hold out for them and hope for the best
d
What the former CEO Mr. Hamza Susie do , He was replace immediately .????? Does the company let has know why Mr.Susie was replaced so fast????? Any News ???????
L
Almost all shares seems like owned by institutionals (Nasdaq website). I've looked at pipeline, oncoming results of a phase 3 and enough cash. (What not to like?) I'm thinking to buy some shares. Bullish and bearish sentiment appreciated, thx
ANAB sunk after news of its failed ATLAS Phase 2b Clinical Trial. ANAB's trades at a considerable 32% discount to its net cash and investments per share of $15.
ANAB sunk after news of its failed ATLAS Phase 2b Clinical Trial. ANAB's trades at a considerable 32% discount to its net cash and investments per share of $15.
seekingalpha.com
V
Smb bought ~21K shares at the opening, MOC volume are increasing 2 day in a row. Going up?
R
This goes down everyday with no apparent news--what gives
G
trading 60% less cash calance + HUGE pipeline = should rebound quickly back to $20 =STRONG BUY its a GIFT
D
I asked several brokers why this stock has been range bound for 5 trading days after dropping 71%. Well, ANAB still hasn't revealed the endpoint studies after its failed ATLAS Phase 2B Clinical Trial. This is highly unusual that a company cancels the trial going forward but won't reveal how bad the end-points are. So, we can presume it is extremely bad. This is why the main share holders dumped and ran for the hills and their is no large institutional buyer moving it up. This is dead in the water until any new news.
G
Book Value $16.60 -- Cash $15.60 ..Partnerships with GSK & Celgene ...late stage programs in Endometrial & Ovarian cancer both partnered with GSK ..and there is a lot more in the pipeline ...
P
Had to buy 10k shares today @10.20 for a rainy day. Panic selling makes me rich.
M
Two things but number one this is a buy in point. we had all these upgrades to 120 and change. more realistic was Credit Suisse downgrades AnaptysBio (NASDAQ:ANAB) from Outperform to Neutral and slashes the price target from $137 to $79, an 18% upside. hey 57 to 79 is attainable and nice profit. we came down not on our data but in regn's in sympathy to theirs. i just bought in again and it really shouldnt go lower. totally oversold.
m
GlaxoSmithKline Reports Received FDA Accelerated Approval For Jemperli For Adult Patients With Mismatch Repair-Deficient Recurrent, Advanced Solid Tumors
-Reuters
m
nice deal. reading between the lines tells that they are raising money in anticipation of approval as we are near trial result. rather than selling stocks.
encouraging news
d
GSK wii buy this company very soon .Why pay all that royalty every year .it will cost less to buy Anapty Bio .
P
Any chart enthusiasts out there? Top of narrow Bollinger Band saying to sell and Elliot Wave signal saying to triple down. What more negative news could be out there. I only see blue skys but paranoid.
J
Insiders dumped their shares last June in the 70's... Gotta watch the insiders
T
Never heard of this biotech until article just released showing promise of peanut allergy treatment. Obviously, this stock tanked lately and over the years. If I were to get in at $11 bucks, thoughts?
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need.
trials failed.
Also not sure about their cash because the $250 million is booked as "liabilities".
In simple english its a kind of a loan....that they do not need to pay back if they met some milestones.
So the real cash is around $300m
Thats $12/share.
If the salesfigures of Jemperli are bad.....
If they are better then expected....
So its a kind of guessing now.
1 thing for sure, they did not find a buyer. Means...nobody saw real value in Anab.
And even they would have success with phase 3 trial. Thats not big money...and will cost $50 tp $ 100 million to start selling it...etc
If XBI will trend up, Anab will go higher from here.
But $37 was good money. Thats why Hamza sold a lot.
https://newsfilter.io/articles/4-form---statement-of-changes-in-beneficial-ownership-of-securities---anaptysbio-inc-0001370053-issu-d07a99fd1d9faa5bcb01d38e8828defa
I've looked at pipeline, oncoming results of a phase 3 and enough cash.
(What not to like?)
I'm thinking to buy some shares.
Bullish and bearish sentiment appreciated, thx
i just bought in again and it really shouldnt go lower. totally oversold.
Adult Patients With Mismatch Repair-Deficient Recurrent, Advanced Solid Tumors
-Reuters
encouraging news
https://www.anaptysbio.com/pipeline/overview/